Teva Pharmaceutical Industries Limited (TEVA)
Automate Your Wheel Strategy on TEVA
With Tiblio's Option Bot, you can configure your own wheel strategy including TEVA - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol TEVA
- Rev/Share 14.5993
- Book/Share 5.5088
- PB 3.1857
- Debt/Equity 2.705
- CurrentRatio 1.0333
- ROIC 0.1146
- MktCap 20086575200.0
- FreeCF/Share 0.9508
- PFCF 18.5643
- PE -15.5246
- Debt/Assets 0.4409
- DivYield 0
- ROE -0.2136
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | TEVA | Truist | -- | Buy | -- | $25 | May 28, 2025 |
| Upgrade | TEVA | JP Morgan | Neutral | Overweight | -- | $23 | May 12, 2025 |
News
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)
Published: February 18, 2025 by: GlobeNewsWire
Sentiment: Neutral
REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept), a biologic used to treat eye disorders, including diseases which can lead to vision loss or blindness. The process to obtain regulatory approval is anticipated to be completed …
Read More
Teva Pharm CEO calls for faster US generic drug approvals
Published: February 17, 2025 by: Reuters
Sentiment: Positive
U.S. President Donald Trump's administration needs to speed up generic drug approvals and exempt some drugs from funding freezes, the CEO of Israel's Teva Pharmaceutical Industries said on Monday.
Read More
Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- Upgrade
Published: February 11, 2025 by: Seeking Alpha
Sentiment: Positive
Axsome Therapeutics, Inc.'s stock has surged over 30% since my last “Hold” rating, driven by key catalysts like the litigation settlement with Teva Pharmaceuticals, announced today. Axsome's Auvelity and Sunosi are crucial, with Auvelity expected to generate over 75% of 2025 revenues; as such, today's news is a significant win. Despite high competition in MDD and other markets, Axsome's pipeline, including AXS-07 and AXS-12, shows potential for substantial revenue growth.
Read More
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva Pharmaceuticals
Published: February 10, 2025 by: Business Wire
Sentiment: Neutral
MONTPELLIER, France--(BUSINESS WIRE)--Medincell (Paris:MEDCL): ACCESS HERE THE FULL PRESS RELEASE.
Read More
About Teva Pharmaceutical Industries Limited (TEVA)
- IPO Date 1982-02-16
- Website https://www.tevapharm.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Mr. Richard D. Francis
- Employees 37000